Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: Three time periods at risk for amputation

Annals of Surgical Oncology

Volumn 14, Issue 4, 2007, Pages 1499-1506

  Van Ginkel, Robert J ^a   Thijssens, Katja M J ^a   Pras, Elisabeth ^a   Van Der Graaf, Winette T A ^a   Suurmeijer, Albert J H ^a   Hoekstra, Harald J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Amputation; Isolated limb perfusion; Late morbidity; Melphalan; Radiotherapy; Sarcoma; Tumor necrosis factor alpha

Indexed keywords

MELPHALAN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AMPUTATION; ANGIOSARCOMA; ARTICLE; BONE NECROSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; EPITHELIOID SARCOMA; FEMALE; FEMUR FRACTURE; FIBROSARCOMA; HUMAN; KAPLAN MEIER METHOD; LEG ISCHEMIA; LEIOMYOSARCOMA; LIMB PERFUSION; LIMB SALVAGE; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; PATHOLOGIC FRACTURE; SEX RATIO; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TUMOR BIOPSY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPUTATION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELPHALAN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34047201444     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9323-2     Document Type: Article

References (38)

1. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982; 196:305-15.
2. Eilber FR, Morton DL, Eckardt J, Grant T, Weisenburger T. Limb salvage for skeletal and soft tissue sarcomas. Multidisciplinary preoperative therapy. Cancer 1984; 53:2579-84.
3. Ham SJ, van der Graaf WT, Pras E, Molenaar WM, Van den Berg E, Hoekstra HJ. Soft tissue sarcoma of the extremities. A multimodality diagnostic and therapeutic approach. Cancer Treat Rev 1998; 24:373-91.
4. Suit HD, Proppe KH, Mankin HJ, Wood WC. Preoperative radiation therapy for sarcoma of soft tissue. Cancer 1981; 47:2269-74.
5. Eilber FR, Mirra JJ, Grant TT, Weisenburger T, Morton DL. Is amputation necessary for sarcomas? A seven-year experience with limb salvage. Ann Surg 1980; 192:431-8.
6. O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002; 359:2235-41.
7. Shiu MH, Hilaris BS, Harrison LB, Brennan MF. Brachy-therapy and function-saving resection of soft tissue sarcoma arising in the limb. Int J Radiat Oncol Biol Phys 1991; 21:1485-92.
8. Krementz ET, Carter RD, Sutherland CM, Hutton I. Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg 1977; 185:555-64.
9. Rossi CR, Vecchiato A, Foletto M, et al. Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer 1994; 73:2140-6.
10. Klaase JM, Kroon BBR, Benckhuijsen C, et al. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 1989; 64:616-21.
11. Pommier RF, Moseley HS, Cohen J, Huang CS, Townsend R, Fletcher WS. Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities. Am J Surg 1988; 155:667-71.
12. van Ginkel RJ, Schraffordt Koops H, de Vries EG, Molenaar WM, Uges DR, Hoekstra HJ. Hyperthermic isolated limb perfusion with cisplatin in four patients with sarcomas of soft tissue and bone. Eur J Surg Oncol 1996; 22:528-31.
13. Daryanani D, de Vries EG, Guchelaar HJ, Van Weerden TW, Hoekstra HJ. Hyperthermic isolated regional perfusion of the limb with carboplatin. Eur J Surg Oncol 2000; 26:792-7.
14. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10:52-60.
15. Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224:756-64.
16. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual 6th ed. New York: Springer-Verlag; 2002.
17. Coindre JM, Trojani M, Contesso G, et al. Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer 1986; 58:306-9.
18. Creech O, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extra-corporeal circuit. Ann Surg 1958; 148:616-32.
19. van Ginkel RJ, Limburg PC, Piers DA, Koops HS, Hoekstra HJ. Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 2002; 9:355-63.
20. Zwaveling JH, Maring JK, Clarke FL, et al. High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan. Crit Care Med 1996; 24:765-70.
21. World Health Organization Handbook for Reporting Results of Cancer Treatment Geneva, Switzerland: World Health Organization; 1979.
22. Kaplan EL, Meier P. Nonparametric estimates from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
23. Noorda EM, Vrouenraets BC, Nieweg OE, van Coevorden F, van Slooten GW, Kroon BB. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer 2003; 98:1483-90.
24. Lejeune FJ, Pujol N, Lienard D, et al. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol 2000; 26:669-78.
25. Gutman M, Inbar M, Lev Shlush D, et al. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a > 90% response rate and limb preservation. Cancer 1997; 79:1129-37.
26. Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Limb salvage by isolated limb perfusion (ILP) with tnf and melphalan in patients with locally advanced soft tissue sarcomas: outcome of 270 ILPs in 246 patients. Proc Am Soc Clin Oncol 1999.
27. Olieman AF, Schraffordt Koops H, et al. Functional morbidity of hyperthermic isolated regional perfusion of the extremities. Ann Surg Oncol 1994; 1:382-8.
28. Vrouenraets BC, Klaase JM, Kroon BBR, Van Geel BN. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs: the influence of acute regional toxic reactions. Arch Surg 1995; 130:43-7.
29. Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1995; 32:1289-300.
30. Johansson S, Svensson H, Denekamp J. Timescale of evolution of late radiation injury after postoperative radiotherapy of breast cancer patients. Int J Radiat Oncol Biol Phys 2000; 48:745-50.
31. Hopewell JW. Early and late changes in the functional vascularity of the hamster cheek pouch after local x-irradiation. Radiat Res 1975; 63:157-64.
32. Hopewell JW. The late vascular effects of radiation (letter). Br J Radiol 1974; 47:157-8.
33. Fajardo LF, Stewart JR. Capillary injury preceding radiation-induced myocardial fibrosis. Radiology 1971; 101:429-33.
34. Lin PP, Boland PJ, Healey JH. Treatment of femoral fractures after irradiation. Clin Orthop 1998; 352:168-78.
35. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta- analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997; 350:1647-54.
36. Delaney TF, Spiro IJ, Suit HD, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2003; 56:1117-27.
37. Kraybill WG, Harris JH, Spiro I, et al. Radiation Therapy Oncology Group (RTOG) 9514: a phase II study of neoadjuvant chemotherapy (CT) and radiation therapy (RT) in the management of high risk (HR), high grade, soft tissue sarcomas (STS) of the extremities and body wall. Proc Am Soc Clin Oncol 2003; 22:815.
38. van Ginkel RJ, Hoekstra HJ, Eggermont AMM, Pras E, Koops HS.. Isolated limb perfusion of an irradiated foot with tumor necrosis factor, interferon, and melphalan. Arch Surg 1996; 131:672-4.